Sunitinib dosing schedule 2/1 improves tolerability, efficacy, and health-related quality of life in Chinese patients with metastatic renal cell carcinoma-Reference-Cited by-同舟云学术

Sunitinib dosing schedule 2/1 improves tolerability, efficacy, and health-related quality of life in Chinese patients with metastatic renal cell carcinoma

Published:2015-06 Issue:6 Volume:33 Page:268.e9-268.e15
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Pan Xiuwu,Huang Hai,Huang Yi,Liu Bing,Cui Xingang^ORCID,Gan Sishun,Ye Jianqing,Xu Danfeng,Chen Lu,Zhou Qiwei,Li Lin,Hong Yi

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference28 articles.

1. Cancer statistics, 2014;Siegel;CA Cancer J Clin,2014

2. Contemporary clinical epidemiology of renal cell carcinoma: insight from a population based case-control study;Miller;J Urol,2010

3. EAU guidelines on renal cell carcinoma: the 2010 update;Ljungberg;Eur Urol,2010

4. Sunitinib in patients with metastatic renal cell carcinoma;Motzer;J Am Med Assoc,2006

5. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship;Mendel;Clin Cancer Res,2003

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sunitinib for Metastatic Renal Cell Carcinoma: Real-World Data from the STAR-TOR Registry and Detailed Literature Review;Urologia Internationalis;2024

2. 2/1 dose schedule of sunitinib is superior than the 4/2 regimen for the first-line therapy of clear cell metastatic renal cell carcinoma – An Indian experience;Indian Journal of Cancer;2023-10

3. Comparative Evaluation of Safety and Efficacy of Alternate Schedule (AS) of Sunitinib in Asian and Non-Asian Patient Population for the Treatment of Metastatic Renal Cell Cancer (mRCC): A Meta-Analysis;Kidney Cancer;2022-03-15

4. Safety and Efficacy of Bis-Glyceryl Ascorbate as Prophylaxis for Hand-Foot Skin Reaction: A Single-Arm, Open-Label Phase I/II Study (DGA Study);The Oncologist;2022-03-14

5. Management of Apatinib-Related Adverse Events in Patients With Advanced Osteosarcoma From Four Prospective Trials: Chinese Sarcoma Study Group Experience;Frontiers in Oncology;2021-07-22